Compare Allstate Corp (ALL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs IDEXX Laboratories, Inc. — how do they compare? Allstate Corp trades at $257.42 (market cap $66.31B), while IDEXX Laboratories, Inc. trades at $571.23 (market cap $46.22B). The key difference: Allstate Corp is the larger of the two by market cap, and Allstate Corp pays a 1.65% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ALL | IDXX | |
|---|---|---|
Market Cap | $66.31B | $46.22B |
Sector | Financials | Health |
52-Week High | $275.11 | $766.68 |
52-Week Low | $190.00 | $526.44 |
Enterprise Value | $74.96B | $47.12B |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $269.67, up 1.0% today, near its 52-week high. The stock shows bullish technical signals with strong support at $267. Fundamentally, the company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. The P/E ratio of 5.25 indicates attractive valuation relative to earnings. Recent news highlights strong operational performance but questions sustainability.
Outlook is positive with earnings beats and dividend payments, but risks include potential normalization of underwriting margins and competitive pressures. Analyst consensus is mixed with a $266.47 price target, suggesting limited upside from current levels. Investment appeal lies in valuation and profitability, though sustainability concerns warrant caution.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
